Abstract: To investigate the antiviral activity of one of the new recombinant consensus interferon α (NIFNcon　α) in vitro. Methods: The cytopathiceffect inhibition assay was applied in this study to investigate the antiviral activity of this drug as well as the other IFNcon α (Infergen) and IFNα as positive control. Vero cells and MDCK cells were infected by different viruses respectively and were cultured with serial dilutions of NIFNcon α. Results: The TD50 of NIFNcon α for MDCK cells and Vero cells was (＞250±0)μg/ml and >192±0?μg/ml， respectively. The IC50 of NIFNcon α for Herpes virus type 1 and type 2 was (2.8×10-4±8.5×10-5) and (1.8×10-4±8.5×10-5) μg/ml, respectively, for coxsackie virus B1 and B3 was (8.8×10-8±1.4×10-8) and (1.5×10-7±4.2×10-8) μg/ml, respectively and for influenza virus A and B was (2.5×10-2±1.2×10-2) and (＞10±0)μg/ml, respectively. Conclusion: The new drug has similar antiviral activities with Infergen, and compare with interferon α, it has more effective antiviral activities for HSV and coxsackie virus except for influenza viruses.

Key words: InterferonⅠ, recombinant, consensus, Cytopathiceffect inhibition assay, Antiviral drug, Orthomyxcviridae,